IBB - （iShares Nasdaq Biotechnology Index Fund）

Shares of Bellerophon Therapeutics Inc. BLPH plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 “Rebuild” study. The company said its INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD) performed worse than placebo, while the secondary endpoints demonstrated “minimal difference” between studied groups, with none approaching statistical significance. The company said it does not see a path forward for continuing the Rebuild trial. The stock has still rallied 33% year to date, while the iShares Biotechnology exchange-traded fund IBB has slipped 1.8% and the S&P 500 SPX has advanced 11.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Shares of Intercept Pharmaceuticals Inc. ICPT tumbled 15.2% toward an 11-month low in premarket trading Monday, after the biopharmaceutical company said a U.S. Food and Drug Administration committee voted to “defer approval” for its treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). The company said 15 of 16 FDA committee members voted to defer approve until clinical outcome data from a trial are submitted and reviewed, and 12 of 16 members voted “no” on the question of whether current efficacy and safety data suggests benefits of the treatment (OCA 25 milligram) outweigh risks in NASH patients. “We are disappointed in the outcome of today’s meeting,” said Intercept Chief Executive Officer Jerry Durso. “We continue to disagree with the FDA on certain characterizations of OCA’s efficacy and safety in pre-cirrhotic fibrosis due to NASH and the role of non-invasive tests (NITs), as discussed in today’s meeting.” Intercept’s stock has gained 9.6% year to date through Friday, while the iShares Biotechnology exchange-traded fund IBB has slipped 0.9% and the S&P 500 SPX has gained 9.2%.

Shares of ImmunityBio Inc. IBRX plummeted 53.7% toward a record one-day selloff in premarket trading Thursday, after the immunotherapy company disclosed it received a “complete response letter” from the U.S. Food and Drug Administration, but puts the company’s Biologics License Application (BLA) for its bladder cancer treatment Anktiva (N-803) on hold. The FDA determined that it can’t approve the BLA in its present form as a pre-license inspection of the company’s third-party contract manufacturer found deficiencies. “The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible,” ImmunityBio said in a statement. Separately, ImmunityBio’s Executive Chairman Patrick Soon-Shiong agreed to provide $30 million in non-convertible debt financing, and the company said it was exploring partnering with a large biopharmaceutical company for commercialization of N-803.

Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen Inc. AMGN to treat Crohn’s disease that could be worth more than $500 million to TScan. Amgen shares slipped 0.1% ahead of the open. Under terms of the collaboration, TScan will receive a $30 million upfront payment, and will be eligible to receive more than $500 million in clinical, regulatory and commercial milestone and royalty payments. The multi-year collaboration will use TScan’s TargetScan to identify antigens recognized by T cells in patients with Crohn’s disease. “We’re excited to apply our target discovery platform to the autoimmunity space,” said TScan Chief Executive Officer Gavin MacBeath. TScan’s stock has run up 45.1% year to date through Monday, while the iShares Biotechnology exchange-traded fund IBB has slipped 0.3% and the S&P 500 SPX has gained 7.8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

Shares of Trevena Inc. TRVN exploded more than five-fold higher — up 420.6% — on very active trading Monday, after the Pennsylvania-based biopharmaceutical company said its China-based partner Jiangsu Nhwa received formal approval from China health regulators for the pain treatment Olinvyk. The stock, which had been halted 21 times for volatility since the open, has seen 75.7 million shares change hands, compared with the full-day average over the past 30 days of about 111,100 shares. Trevena said Olinvyk, which was approved by the U.S. Food and Drug Administration in August 2020, has been approved by China’s National Medical Products Administration (NMPA) for use in adults to treat acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Trevena is in line to receive a $3 million milestone payment from Jiangsu Nhwa, and is also eligible to receive $15 million upon the first commercial sales of Olinvyk in China. Trevena’s stock has now rallied 129.4% year to date, while the iShares Biotechnology exchange-traded fund IBB has slipped 0.5% and the S&P 500 SPX has gained 7.7%.

Related Stocks: CMG , IVV , SBUX , XBI , IBB ,

These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market in some segments of the market even during these gloomy weeks. Fears of sticky inflation and recession led to many investors reevaluating their investments or pulling their money out of the stock markets altogether. As a result, the S&P 500 index has dropped 23% year to date, while the tech-heavy NASDAQ 100 has lost close to a third of its value. However, for investors who research further, there is always a chance to find the best stocks to buy in a hidden bull market. Including several of those shares could help boost the performance of investment portfolios despite the overall market chaos. Even in 2022, with interest rates hitting a 14-year high in the U.S. and stocks getting hammered, we are experiencing localized bull markets in the energy and utility sectors. For instance, the energy sector, overall, has returned around 18% since January.

Health care stocks were mixed pre-bell Friday. The Health Care SPDR (XLV) was advancing by 0.30% and the iShares NASDAQ Biotechnology Index (IBB) was recently down by 0.05%.

WALL, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (NASDAQ: BKYI ), an innovative provider of workforce and customer identity and access management (IAM) and large-scale identity solutions, featuring Identity-Bound Biometrics (IBB), today reported results for its second quarter ended June 30, 2022 (Q2''22). BIO-key is hosting a conference call today at 10:00 a.m. ET (details below) to review its results and outlook. Highlights: Q2''22 revenues rose 96% to $1.9M from $1.0M in Q2''21 , driven by a $0.5M increase in software license fees, as well as $0.3M and $0.15M increases in hardware and services revenue, respectively. Expanded PortalGuard Penetration with new customers, including YYK Enterprises Operations and a Texas City and New Channel Alliance Program partners, including the Amazon Web Services Partner Network , 3Eye Technologies and Darksteel Technologies . BIO-key''s PortalGuard® platform was a gold recipient of Security Today magazine''s 2022 Govies Government Security Award in User Authentication/Identification/Credentialing and Management; the Publisher''s Choice for Multi-factor Authentication (MFA) Award from Cyber Defense Magazine during RSA 2022; the 2022 Fortress Cyber Security Award in Authentication and Identity ; and RemoteTech Breakthrough''s Identity Management Solution of the Year 2022 .

In trading on Monday, shares of the iShares Biotechnology ETF (Symbol: IBB) crossed above their 200 day moving average of $132.09, changing hands as high as $133.14 per share. iShares Biotechnology shares are currently trading up about 1.1% on the day. The chart below shows t

These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market in some segments of the market even during these gloomy weeks. Fears of sticky inflation and recession led to many investors reevaluating their investments or pulling their money out of the stock markets altogether. As a result, the S&P 500 index has dropped 23% year to date, while the tech-heavy NASDAQ 100 has lost close to a third of its value. However, for investors who research further, there is always a chance to find the best stocks to buy in a hidden bull market. Including several of those shares could help boost the performance of investment portfolios despite the overall market chaos. Even in 2022, with interest rates hitting a 14-year high in the U.S. and stocks getting hammered, we are experiencing localized bull markets in the energy and utility sectors. For instance, the energy sector, overall, has returned around 18% since January.

Health care stocks were mixed pre-bell Friday. The Health Care SPDR (XLV) was advancing by 0.30% and the iShares NASDAQ Biotechnology Index (IBB) was recently down by 0.05%.

WALL, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (NASDAQ: BKYI ), an innovative provider of workforce and customer identity and access management (IAM) and large-scale identity solutions, featuring Identity-Bound Biometrics (IBB), today reported results for its second quarter ended June 30, 2022 (Q2''22). BIO-key is hosting a conference call today at 10:00 a.m. ET (details below) to review its results and outlook. Highlights: Q2''22 revenues rose 96% to $1.9M from $1.0M in Q2''21 , driven by a $0.5M increase in software license fees, as well as $0.3M and $0.15M increases in hardware and services revenue, respectively. Expanded PortalGuard Penetration with new customers, including YYK Enterprises Operations and a Texas City and New Channel Alliance Program partners, including the Amazon Web Services Partner Network , 3Eye Technologies and Darksteel Technologies . BIO-key''s PortalGuard® platform was a gold recipient of Security Today magazine''s 2022 Govies Government Security Award in User Authentication/Identification/Credentialing and Management; the Publisher''s Choice for Multi-factor Authentication (MFA) Award from Cyber Defense Magazine during RSA 2022; the 2022 Fortress Cyber Security Award in Authentication and Identity ; and RemoteTech Breakthrough''s Identity Management Solution of the Year 2022 .

In trading on Monday, shares of the iShares Biotechnology ETF (Symbol: IBB) crossed above their 200 day moving average of $132.09, changing hands as high as $133.14 per share. iShares Biotechnology shares are currently trading up about 1.1% on the day. The chart below shows t

Health care stocks were leaning lower premarket Monday. The Health Care SPDR (XLV) was down 0.3% and the iShares NASDAQ Biotechnology Index (IBB) was recently slipping by 0.5%.